May 24, 2022
Attorneys for investors in Danish pharmaceutical giant Novo Nordisk have requested nearly a third of a $100 million settlement that, if approved, would resolve claims the company hurt shareholders by failing to disclose "increasingly large kickbacks" it allegedly paid pharmacy benefit managers to get its products on lists of drugs recommended to providers.
September 24, 2021
Novo Nordisk announced Friday that it has reached a $100 million settlement in an investor class action alleging the Danish pharmaceutical giant boasted about its finances while concealing a scheme to pay kickbacks to pharmacy benefit managers to get its insulin drugs on stores' recommended product lists.
January 31, 2020
A New Jersey federal judge on Friday granted certification to a class of Novo Nordisk investors in a suit alleging the Danish pharmaceutical giant misled shareholders about the driving forces behind its financial growth while concealing a scheme to pay kickbacks to pharmacy benefit managers in exchange for access to the insulin marketplace.
April 02, 2019
Five retirement plans have pressed a New Jersey federal judge for class certification in their suit accusing Novo Nordisk of boasting about its finances while concealing a scheme to pay off pharmacy benefit managers to get its insulin drugs on stores' recommended product lists.
August 16, 2018
A New Jersey federal judge on Thursday refused to toss a putative class action accusing Novo Nordisk of misleading shareholders about its financial sustainability in the U.S. market, ruling that the investors had sufficiently alleged that the Danish insulin maker made materially misleading statements about its rebate program and the pricing pressures facing its drug Tresiba.